Overexpression of Parkinson’s disease-associated mutation LRRK2 G2019S in mouse forebrain induces behavioral deficits and α-synuclein pathology

Yulan Xiong, Stewart Neifert, Senthilkumar Karuppagounder, Jeannette N. Stankowski, Byoung Dae Lee, Jonathan C. Grima, Guanxing Chen, Hanseok Seok Ko, Yunjong Lee, Debbie Swing, Lino Tessarollo, Ted M Dawson, Valina Dawson

Research output: Contribution to journalArticle

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified as an unambiguous cause of late-onset, autosomal-dominant familial Parkinson’s disease (PD) and LRRK2 mutations are the strongest genetic risk factor for sporadic PD known to date. A number of transgenic mice expressing wild-type or mutant LRRK2 have been described with varying degrees of LRRK2-related abnormalities and modest pathologies. None of these studies directly addressed the role of the kinase domain in the changes observed and none of the mice present with robust features of the human disease. In an attempt to address these issues, we created a conditional LRRK2 G2019S (LRRK2 GS) mutant and a functionally negative control, LRRK2 G2019S/D1994A (LRRK2 GS/DA). Expression of LRRK2 GS or LRRK2 GS/DA was conditionally controlled using the tet-off system in which the presence of tetracycline-transactivator protein (tTA) with a CAMKIIα promoter (CAMKIIα-tTA) induced expression of TetP-LRRK2 GS or TetP-LRRK2 GS/DA in the mouse forebrain. Overexpression of LRRK2 GS in mouse forebrain induced behavioral deficits and α-synuclein pathology in a kinase-dependent manner. Similar to other genetically engineered LRRK2 GS mice, there was no significant loss of dopaminergic neurons. These mice provide an important new tool to study neurobiological changes associated with the increased kinase activity from the LRRK2 G2019S mutation, which may ultimately lead to a better understanding of not only the physiologic actions of LRRK2, but also potential pathologic actions that underlie LRRK2 GS-associated PD.

Original languageEnglish (US)
Article numbere0004
JournaleNeuro
Volume4
Issue number2
DOIs
StatePublished - 2017

Fingerprint

Synucleins
Prosencephalon
Leucine
Parkinson Disease
Phosphotransferases
Pathology
Mutation
Trans-Activators
Tetracycline

Keywords

  • LRRK2
  • Parkinson’s disease
  • Transgenic mice
  • α-synuclein

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Overexpression of Parkinson’s disease-associated mutation LRRK2 G2019S in mouse forebrain induces behavioral deficits and α-synuclein pathology. / Xiong, Yulan; Neifert, Stewart; Karuppagounder, Senthilkumar; Stankowski, Jeannette N.; Lee, Byoung Dae; Grima, Jonathan C.; Chen, Guanxing; Ko, Hanseok Seok; Lee, Yunjong; Swing, Debbie; Tessarollo, Lino; Dawson, Ted M; Dawson, Valina.

In: eNeuro, Vol. 4, No. 2, e0004, 2017.

Research output: Contribution to journalArticle

Xiong, Yulan ; Neifert, Stewart ; Karuppagounder, Senthilkumar ; Stankowski, Jeannette N. ; Lee, Byoung Dae ; Grima, Jonathan C. ; Chen, Guanxing ; Ko, Hanseok Seok ; Lee, Yunjong ; Swing, Debbie ; Tessarollo, Lino ; Dawson, Ted M ; Dawson, Valina. / Overexpression of Parkinson’s disease-associated mutation LRRK2 G2019S in mouse forebrain induces behavioral deficits and α-synuclein pathology. In: eNeuro. 2017 ; Vol. 4, No. 2.
@article{0ace25e3de5b43708d20b13d6bc1b114,
title = "Overexpression of Parkinson’s disease-associated mutation LRRK2 G2019S in mouse forebrain induces behavioral deficits and α-synuclein pathology",
abstract = "Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified as an unambiguous cause of late-onset, autosomal-dominant familial Parkinson’s disease (PD) and LRRK2 mutations are the strongest genetic risk factor for sporadic PD known to date. A number of transgenic mice expressing wild-type or mutant LRRK2 have been described with varying degrees of LRRK2-related abnormalities and modest pathologies. None of these studies directly addressed the role of the kinase domain in the changes observed and none of the mice present with robust features of the human disease. In an attempt to address these issues, we created a conditional LRRK2 G2019S (LRRK2 GS) mutant and a functionally negative control, LRRK2 G2019S/D1994A (LRRK2 GS/DA). Expression of LRRK2 GS or LRRK2 GS/DA was conditionally controlled using the tet-off system in which the presence of tetracycline-transactivator protein (tTA) with a CAMKIIα promoter (CAMKIIα-tTA) induced expression of TetP-LRRK2 GS or TetP-LRRK2 GS/DA in the mouse forebrain. Overexpression of LRRK2 GS in mouse forebrain induced behavioral deficits and α-synuclein pathology in a kinase-dependent manner. Similar to other genetically engineered LRRK2 GS mice, there was no significant loss of dopaminergic neurons. These mice provide an important new tool to study neurobiological changes associated with the increased kinase activity from the LRRK2 G2019S mutation, which may ultimately lead to a better understanding of not only the physiologic actions of LRRK2, but also potential pathologic actions that underlie LRRK2 GS-associated PD.",
keywords = "LRRK2, Parkinson’s disease, Transgenic mice, α-synuclein",
author = "Yulan Xiong and Stewart Neifert and Senthilkumar Karuppagounder and Stankowski, {Jeannette N.} and Lee, {Byoung Dae} and Grima, {Jonathan C.} and Guanxing Chen and Ko, {Hanseok Seok} and Yunjong Lee and Debbie Swing and Lino Tessarollo and Dawson, {Ted M} and Valina Dawson",
year = "2017",
doi = "10.1523/ENEURO.0004-17.2017",
language = "English (US)",
volume = "4",
journal = "eNeuro",
issn = "2373-2822",
publisher = "Society for Neuroscience",
number = "2",

}

TY - JOUR

T1 - Overexpression of Parkinson’s disease-associated mutation LRRK2 G2019S in mouse forebrain induces behavioral deficits and α-synuclein pathology

AU - Xiong, Yulan

AU - Neifert, Stewart

AU - Karuppagounder, Senthilkumar

AU - Stankowski, Jeannette N.

AU - Lee, Byoung Dae

AU - Grima, Jonathan C.

AU - Chen, Guanxing

AU - Ko, Hanseok Seok

AU - Lee, Yunjong

AU - Swing, Debbie

AU - Tessarollo, Lino

AU - Dawson, Ted M

AU - Dawson, Valina

PY - 2017

Y1 - 2017

N2 - Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified as an unambiguous cause of late-onset, autosomal-dominant familial Parkinson’s disease (PD) and LRRK2 mutations are the strongest genetic risk factor for sporadic PD known to date. A number of transgenic mice expressing wild-type or mutant LRRK2 have been described with varying degrees of LRRK2-related abnormalities and modest pathologies. None of these studies directly addressed the role of the kinase domain in the changes observed and none of the mice present with robust features of the human disease. In an attempt to address these issues, we created a conditional LRRK2 G2019S (LRRK2 GS) mutant and a functionally negative control, LRRK2 G2019S/D1994A (LRRK2 GS/DA). Expression of LRRK2 GS or LRRK2 GS/DA was conditionally controlled using the tet-off system in which the presence of tetracycline-transactivator protein (tTA) with a CAMKIIα promoter (CAMKIIα-tTA) induced expression of TetP-LRRK2 GS or TetP-LRRK2 GS/DA in the mouse forebrain. Overexpression of LRRK2 GS in mouse forebrain induced behavioral deficits and α-synuclein pathology in a kinase-dependent manner. Similar to other genetically engineered LRRK2 GS mice, there was no significant loss of dopaminergic neurons. These mice provide an important new tool to study neurobiological changes associated with the increased kinase activity from the LRRK2 G2019S mutation, which may ultimately lead to a better understanding of not only the physiologic actions of LRRK2, but also potential pathologic actions that underlie LRRK2 GS-associated PD.

AB - Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified as an unambiguous cause of late-onset, autosomal-dominant familial Parkinson’s disease (PD) and LRRK2 mutations are the strongest genetic risk factor for sporadic PD known to date. A number of transgenic mice expressing wild-type or mutant LRRK2 have been described with varying degrees of LRRK2-related abnormalities and modest pathologies. None of these studies directly addressed the role of the kinase domain in the changes observed and none of the mice present with robust features of the human disease. In an attempt to address these issues, we created a conditional LRRK2 G2019S (LRRK2 GS) mutant and a functionally negative control, LRRK2 G2019S/D1994A (LRRK2 GS/DA). Expression of LRRK2 GS or LRRK2 GS/DA was conditionally controlled using the tet-off system in which the presence of tetracycline-transactivator protein (tTA) with a CAMKIIα promoter (CAMKIIα-tTA) induced expression of TetP-LRRK2 GS or TetP-LRRK2 GS/DA in the mouse forebrain. Overexpression of LRRK2 GS in mouse forebrain induced behavioral deficits and α-synuclein pathology in a kinase-dependent manner. Similar to other genetically engineered LRRK2 GS mice, there was no significant loss of dopaminergic neurons. These mice provide an important new tool to study neurobiological changes associated with the increased kinase activity from the LRRK2 G2019S mutation, which may ultimately lead to a better understanding of not only the physiologic actions of LRRK2, but also potential pathologic actions that underlie LRRK2 GS-associated PD.

KW - LRRK2

KW - Parkinson’s disease

KW - Transgenic mice

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=85032154444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032154444&partnerID=8YFLogxK

U2 - 10.1523/ENEURO.0004-17.2017

DO - 10.1523/ENEURO.0004-17.2017

M3 - Article

C2 - 28321439

AN - SCOPUS:85032154444

VL - 4

JO - eNeuro

JF - eNeuro

SN - 2373-2822

IS - 2

M1 - e0004

ER -